MedTrace Pharma A/S Secures $10M to Revolutionize Perfusion Imaging with 15O-Water PET Breakthrough

MedTrace Pharma A/S is thrilled to announce that it has successfully raised 10,000,000 in its latest funding round, a significant milestone aimed at accelerating its mission to minimize diagnostic uncertainty through advanced perfusion imaging. With this capital injection, the company is well-positioned to further develop and refine its groundbreaking solution that leverages the PET tracer 15O-water—widely recognized as the gold standard for non-invasive blood flow quantification—to enable absolute measurements of blood flow. MedTrace’s innovative approach integrates an onsite cyclotron with its PET scanner setup, coupled with a robust software package designed to quantify myocardial blood flow and overall perfusion, thereby empowering healthcare providers with rapid, precise diagnostic insights. This infusion of funds reflects the strong confidence of investors in MedTrace’s vision and technological prowess, underlining a broader commitment within the medical community to enhance diagnostic accuracy and patient care. The raised capital will be strategically allocated to support ongoing clinical evaluations, further technological advancements, and efforts to expand the solution’s reach within regulated environments. It is important to note that while MedTrace’s products are not yet cleared for routine use in all markets, the company is actively pursuing compliance and regulatory pathways, including ongoing clinical trials in the United States and adherence to national drug authority rules throughout Europe. This funding not only bolsters MedTrace’s research and development initiatives but also serves as a promising step toward transforming how clinicians assess and manage perfusion-related challenges, ultimately contributing to a future where diagnostic uncertainty is significantly reduced, leading to improved patient outcomes worldwide.